Page last updated: 2024-12-11
lankacidins
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
lankacidins: RN refers to lankacidin C; RN given refers to (1S-(1R*,2S*,3E,5E,7R*,9E,11E,13R*,15S*,19S*))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6440871 |
CHEBI ID | 80085 |
MeSH ID | M0051938 |
Synonyms (25)
Synonym |
---|
lankacidin |
propanamide, n-(7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo(13.2.2)nonadeca-3,5,9,11-tetraen-2-yl)-2-oxo-, (1s-(1r*,2s*,3e,5e,7r*,9e,11e,13r*,15s*,19s*))- |
antibiotic t-2636 c |
pyruvamide, n-(7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo(13.2.2)nonadeca-3,5,9,11-tetraen-2-yl)-, (all-e)-(1s,2r,7s,13s,15r,19r)-(-)- |
bundlin a |
lankacidins |
nsc 145118 |
chebi:80085 , |
lankacidin c |
23623-31-6 |
t 2636c |
nsc-145118 |
t-2636c |
n-[(1s,2r,3e,5e,7s,9e,11e,13s,15r,19r)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxopropanamide |
j5w73r54rl , |
unii-j5w73r54rl |
lankacidin c, (-)- |
antibiotic t 2636c |
(-)-lankacidin c |
propanamide, n-((1s,2r,3e,5e,7s,9e,11e,13s,15r,19r)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo(13.2.2)nonadeca-3,5,9,11-tetraen-2-yl)-2-oxo- |
ATDILMLBOZKFGI-JUTMVFGESA-N |
Q27149238 |
CS-0081975 |
HY-121412 |
DTXSID701037257 |
Research Excerpts
Overview
Lankacidins are a group of polyketide natural products with activity against several strains of Gram-positive bacteria. They have not been deployed as therapeutics due to their chemical instability.
Excerpt | Reference | Relevance |
---|---|---|
"Lankacidins are a class of polyketide natural products isolated from " | ( Modular Approaches to Lankacidin Antibiotics. Cai, L; Seiple, IB; Yao, Y; Yeon, SK, 2020) | 2 |
"Lankacidins are a group of polyketide natural products with activity against several strains of Gram-positive bacteria but have not been deployed as therapeutics due to their chemical instability." | ( Modular Chemical Synthesis of Streptogramin and Lankacidin Antibiotics. Cai, L; Li, Q; Seiple, IB, 2021) | 1.34 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
organic molecular entity | Any molecular entity that contains carbon. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (29)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (10.34) | 18.7374 |
1990's | 3 (10.34) | 18.2507 |
2000's | 7 (24.14) | 29.6817 |
2010's | 12 (41.38) | 24.3611 |
2020's | 4 (13.79) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.48
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.48) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (3.45%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 28 (96.55%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |